Abstract 452P
Background
Cancer is the leading cause of death worldwide. In 2012, around 8,2 million deaths were caused by cancer.1 Chemotherapy in cancer patients is often accompanied by bone marrow aplasia which manifests as anemia. The choice of therapy for anemia in cancer patients are blood transfusions. In addition, an Erythropoiesis-Stimulating Agent (ESA) can be added which can increase the production of erythrocytes in the bone marrow.17,18 Increased erythropoeisis process induced by ESA will bind to Erythropoietin Receptor (EpoR) on the erythropoetic cell surface in the bone marrow. In other hand, ESA therapy were still not giving a satisfied result and still lack of data about expression of EpoR. Absolute reticulocyte count (ARC) is a marker of erythrocyte production that is more accurate in distinguishing hypo or hyperproliferative anemia.
Methods
This study was an observational analytic, cross sectional study carried out at the hematology specialty clinic, integrated oncology unit, Department of Internal Medicine, Dr. M. Djamil Padang Hospital for 6 months. A sample of 30 patients who met the inclusion and exclusion criteria. Initial screening for potential subjects was carried out, the research protocol was explained and informed consent was requested.
Results
There is a decrease of EpoR expression (8481,33±5364,46 copies/uL) compared to normal value (34-3000 x 103 copies/uL). There is also a decrease of ARC (27,97±9,24 x109/L) compared to normal value (50-100 x109/L). Positive correlation was found between EpoR expression and ARC. In the statistical test using the Pearson test it was found that the correlation was significant (p < 0.05) with very strong gradations (r = 0.819).
Conclusions
There is a decrease the average of EpoR expression in patient with anemia related chemotherapy and significant positive correlation with a very strong gradation between EpoR expression and ACR .
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Division of Hematology and Medical Oncology, Internal Medicine Department, Dr. M. Djamil General Hospital, Padang, Indonesia.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract